Immunotherapy Archives

March 21, 2022

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges

Immunotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma or CLL/SLL holds the promise of harnessing the body’s immune system to recognize and eliminate cancer.

December 4, 2020

ASH 2019: Dr. Adrian Wiestner on Bispecific Antibodies for Treating CLL (Chronic Lymphocytic Leukemia)

Also during ASH 2019, Dr. Koffman interviewed Dr. Adrian Wiestner, who discussed bi-specific antibodies to improve the immune system in CLL patients. There is reason to believe that when used in combination with a BTK inhibitor such as ibrutinib, they would have increased effectiveness, as ibrutinib improves T cell

December 4, 2020

ASH 2019: Dr. Krish Patel on Harnessing the Immune System in Chronic Lymphocytic Leukemia (CLL) and Other Lymphomas Using Bispecific Antibodies

Dr. Brian Koffman interviewed Dr. Krish Patel at ASH 2019, about how our native immune system is excellent at controlling cancer when it is working normally. In CLL, the immune system has become dysregulated and does a poor job controlling cancer. Could modifying the immune system with off-the-shelf bi-specific

September 10, 2020

ASH 2019: Dr. Neil Kay on Ibrutinib and Rituximab for Chronic Lymphocytic Leukemia (CLL)

The ECOG (E1912) Phase III, randomized, open label, clinical trial, comparing the efficacy of combination ibrutinib and rituximab with standard chemo-immunotherapy (FCR in patients 70 years of age or younger with previously untreated CLL) was a huge game-changer for CLL patients. We are happy to share with you Dr.

June 24, 2020

Bispecific Antibodies: what are they and are they the future of treatment for CLL (chronic lymphocytic leukemia)?

June 24, 2020

ASH 2019: Dr. Schuster on Mosunetuzumab, a Bispecific Antibody in Poor Prognosis Non-Hodgkin Lymphoma Patients

August 11, 2019

Biosimilars

“Biosimilars” are equivalent versions of monoclonal antibodies that have previously been FDA approved to treat various diseases. Because antibodies are more complicated than simple drugs like acetaminophen and aspirin, etc., these drugs are not chemically identical to the original drug. The main advantage of biosimilars is the reduction in

August 6, 2019

Ibrutinib and Rituximab (IR) is Superior to Chemo-immunotherapy (CIT) in CLL: Big News, or is it really? And did they get it right?

When CNN has a headline that Chemo-free drug combo shows ‘dramatic’ improvement against common leukemia in adults and reports on a medical journal article on a rare disease such as CLL that’s big news, isn’t it? When New England Journal of Medicine (NEJM), arguably the most prestigious medical journal

August 30, 2016

ASH 2015: Dr. Castro on HDMP and Obinutuzumab for CLL

Dr. Januario Castro and the other doctors at the University of California, San Diego Moores Cancer Center have pushed for and pioneered non-chemo approaches to treat chronic lymphocytic leukemia (CLL) for many years. At ASH 2015, he discussed his results with the one of the very first and longest-established

Immunotherapy

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges

ASH 2019: Dr. Adrian Wiestner on Bispecific Antibodies for Treating CLL (Chronic Lymphocytic Leukemia)

ASH 2019: Dr. Krish Patel on Harnessing the Immune System in Chronic Lymphocytic Leukemia (CLL) and Other Lymphomas Using Bispecific Antibodies

ASH 2019: Dr. Neil Kay on Ibrutinib and Rituximab for Chronic Lymphocytic Leukemia (CLL)

Bispecific Antibodies: what are they and are they the future of treatment for CLL (chronic lymphocytic leukemia)?

ASH 2019: Dr. Schuster on Mosunetuzumab, a Bispecific Antibody in Poor Prognosis Non-Hodgkin Lymphoma Patients

Biosimilars

Ibrutinib and Rituximab (IR) is Superior to Chemo-immunotherapy (CIT) in CLL: Big News, or is it really? And did they get it right?

ASH 2015: Dr. Castro on HDMP and Obinutuzumab for CLL

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT